VERU - Veru Inc Stock Price, Fair Value and News

1.30USD-0.07 (-5.11%)Market Closed

Market Summary

USD1.30-0.07

Market Closed

-5.11%

VERU Stock Price

View Fullscreen

VERU RSI Chart

VERU Valuation

Market Cap

190.3M

Price/Earnings (Trailing)

-4.88

Price/Sales (Trailing)

14.12

EV/EBITDA

-5.13

Price/Free Cashflow

-5.16

VERU Price/Sales (Trailing)

VERU Profitability

EBT Margin

-283.64%

Return on Equity

-86.17%

Return on Assets

-54.26%

Free Cashflow Yield

-19.37%

VERU Fundamentals

VERU Revenue

Revenue (TTM)

13.5M

Rev. Growth (Yr)

-37.21%

Rev. Growth (Qtr)

93.17%

VERU Earnings

Earnings (TTM)

-39.0M

Earnings Growth (Yr)

70.33%

Earnings Growth (Qtr)

-21.15%

Breaking Down VERU Revenue

Last 7 days

-2.3%

Last 30 days

12.1%

Last 90 days

170.8%

Trailing 12 Months

15.0%

How does VERU drawdown profile look like?

VERU Financial Health

Current Ratio

4.72

Debt/Equity

0.04

Debt/Cashflow

-23.26

VERU Investor Care

Dividend Yield

14.79%

Dividend/Share (TTM)

0.21

Shares Dilution (1Y)

64.04%

Diluted EPS (TTM)

-0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.5M	0	0	0
2023	21.3M	15.0M	16.3M	15.9M
2022	60.5M	52.4M	39.4M	27.7M
2021	50.0M	57.4M	61.3M	60.8M
2020	39.0M	39.6M	42.6M	46.6M
2019	24.1M	28.3M	31.8M	36.0M
2018	13.2M	14.4M	15.9M	19.6M
2017	14.8M	13.5M	13.7M	13.0M
2016	28.0M	25.7M	22.1M	17.1M
2015	31.1M	31.0M	32.6M	34.2M
2014	23.1M	23.7M	24.5M	24.5M
2013	38.0M	36.6M	31.5M	28.2M
2012	27.1M	32.2M	35.0M	36.3M
2011	20.4M	19.5M	18.6M	23.5M
2010	0	24.9M	22.2M	21.3M
2009	0	0	27.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Veru Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 15, 2022	eisenberger mario	acquired	156,950	1.5695	100,000	-
Aug 15, 2022	eisenberger mario	sold	-2,003,550	20.0355	-100,000	-
Aug 17, 2021	lu lucy	bought	32,542	6.7796	4,800	-
Jun 16, 2021	fisch harry	sold	-835,300	8.353	-100,000	-
Mar 10, 2021	hyun grace	bought	49,315	14.09	3,500	-
Feb 12, 2021	steiner mitchell shuster	sold	-417,688	20.8844	-20,000	president and ceo
Dec 16, 2020	steiner mitchell shuster	sold	-2,421,620	9.6865	-250,000	president and ceo
Dec 16, 2020	barnette k gary	sold	-1,064,510	10.6451	-100,000	chief scientific officer
Aug 26, 2020	fisch harry	bought	13,799	2.7599	5,000	-
Aug 24, 2020	greco michele	bought	13,233	2.6466	5,000	cao and cfo

Which funds bought or sold VERU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	new	-	662,563	662,563	0.07%
May 16, 2024	AWM Investment Company, Inc.	sold off	-100	-1,980,000	-	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-51,991	-	-%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	-111,135	3,909,850	0.07%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.07	-2,322	79,270	-%
May 15, 2024	MORGAN STANLEY	added	0.06	-53,152	1,912,530	-%
May 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	reduced	-14.46	-2,000	9,000	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-1,000	45,000	-%
May 15, 2024	Paradigm Financial Partners, LLC	unchanged	-	-398	14,002	-%
May 15, 2024	DEUTSCHE BANK AG\	new	-	1,053	1,053	-%

Are Funds Buying or Selling VERU?

Are funds buying VERU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERU

No. of Funds

Unveiling Veru Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 24, 2024	millennium management llc	5.2%	7,600,502	SC 13G
Feb 14, 2024	perceptive advisors llc	3.8%	5,584,699	SC 13G/A
Feb 06, 2024	frost phillip md et al	3.5%	5,100,253	SC 13G/A
Dec 26, 2023	adage capital partners gp, l.l.c.	9.50%	13,722,222	SC 13G
Dec 08, 2023	morgan stanley	4.2%	3,756,588	SC 13G/A
Sep 28, 2023	frost phillip md et al	5.7%	5,100,253	SC 13G/A
Jun 08, 2023	blackrock inc.	4.98%	4,421,516	SC 13G/A
Apr 19, 2023	frost phillip md et al	6.1%	5,000,253	SC 13G
Feb 14, 2023	tang capital partners lp	0.0%	0	SC 13G/A
Feb 14, 2023	perceptive advisors llc	9.7%	7,858,011	SC 13G

Recent SEC filings of Veru Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	DEFA14A	DEFA14A
May 09, 2024	DEFR14A	DEFR14A
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report

Peers (Alternatives to Veru Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Veru Inc News

Latest updates

Veru Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	93.2%	4,135,301	2,140,726	3,862,012	3,341,185	6,585,967	2,507,794	2,588,631	9,602,195	13,028,394	14,135,132	15,646,460	17,655,592	13,340,487	14,616,989	11,749,186	10,321,754	9,943,104	10,578,016	8,728,403	9,727,060	6,976,115
Gross Profit	-41.0%	678,299	1,150,452	1,541,180	1,230,618	4,092,075	702,055	505,405	7,068,623	11,175,278	11,842,082	12,309,178	13,873,112	10,908,300	10,836,633	9,562,147	6,519,118	7,436,498	7,269,095	5,832,733	6,571,158	4,608,851
Operating Expenses	6.2%	10,567,131	9,951,481	10,717,314	19,690,552	38,506,909	38,156,992	45,442,539	28,892,398	22,940,242	16,804,367	14,180,404	16,744,976	12,379,710	10,059,634	6,731,918	7,911,970	7,736,176	9,053,488	7,290,308	8,413,160	6,733,441
S&GA Expenses	-8.7%	7,580,340	8,301,431	6,774,559	10,902,916	12,834,494	17,545,865	18,290,515	10,761,486	7,401,138	6,723,206	5,924,812	5,556,730	4,806,897	4,381,880	3,463,426	3,475,474	3,805,916	3,753,514	3,685,006	3,547,046	3,822,854
R&D Expenses	81.0%	2,986,791	1,650,050	3,942,755	8,787,636	17,860,701	20,611,127	27,155,024	18,133,412	15,541,104	10,081,161	8,255,592	11,188,246	7,572,813	5,677,754	3,268,492	4,436,496	3,930,260	5,299,974	3,605,302	4,866,114	2,910,587
EBITDA Margin	27.6%	-2.75	-3.80	-5.53	-8.20	-6.21	-4.04	-2.01	-0.81	-0.42	-0.23	0.15	0.02	0.07	-	-	-	-	-	-	-	-
Interest Expenses	-11.9%	145,310	164,957	207,201	648,917	697,693	873,230	812,321	1,185,093	1,212,702	1,158,682	1,157,795	1,287,525	1,251,551	1,189,183	1,145,343	1,169,692	1,164,962	1,141,425	1,078,085	1,091,276	1,258,272
Income Taxes	351.2%	182,002	-72,439	557,492	57,551	-66,559	-68,278	11,589	137,603	-27,450	114,655	-356,067	-2,873,063	21,690	78,302	-1,109,060	240,502	-133,140	-76,743	-421,140	-458	25,167
Earnings Before Taxes	-17.9%	-9,843,946	-8,348,420	-7,574,623	-12,465,095	-33,855,533	-38,777,235	-41,275,617	-22,057,973	-14,205,280	-6,265,351	-4,650,547	-5,565,929	-2,824,291	17,306,003	-12,941,605	-2,784,878	-943,649	-3,381,844	-3,481,597	-2,774,534	-4,008,868
EBT Margin	27.4%	-2.84	-3.91	-5.69	-8.41	-6.39	-4.20	-2.13	-0.90	-0.51	-0.32	0.07	-0.07	-0.02	-	-	-	-	-	-	-	-
Net Income	-21.1%	-10,025,948	-8,275,981	-8,132,115	-12,522,646	-33,788,974	-38,708,957	-41,287,206	-22,195,576	-14,177,830	-6,380,006	-4,294,480	-2,692,866	-2,845,981	17,227,701	-11,832,545	-3,025,380	-810,509	-3,305,101	-3,060,457	-2,774,076	-4,034,035
Net Income Margin	26.6%	-2.89	-3.94	-5.72	-8.41	-6.39	-4.20	-2.14	-0.90	-0.46	-0.27	0.12	0.00	-0.01	-	-	-	-	-	-	-	-
Free Cashflow	5.9%	-5,862,915	-6,233,263	-9,705,334	-18,457,329	-25,697,258	-34,819,593	-21,027,305	-14,118,848	-4,131,902	-8,960,001	-1,028,701	-12,976,589	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.9%	72.00	81.00	50.00	60.00	70.00	101	135	161	173	172	178	180	181	73.00	52.00	65.00	56.00	55.00	54.00	54.00	51.00
Current Assets	-15.4%	45.00	53.00	23.00	33.00	43.00	70.00	104	128	140	146	152	154	156	48.00	27.00	27.00	17.00	17.00	17.00	17.00	14.00
Cash Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.00	6.00
Inventory	-30.5%	5.00	7.00	7.00	6.00	8.00	9.00	9.00	8.00	6.00	5.00	6.00	7.00	8.00	7.00	7.00	5.00	6.00	5.00	4.00	3.00	3.00
Net PPE	-1.7%	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
Liabilities	-8.2%	27.00	29.00	30.00	40.00	49.00	52.00	53.00	44.00	37.00	24.00	26.00	25.00	26.00	24.00	21.00	24.00	25.00	25.00	21.00	19.00	17.00
Current Liabilities	-42.5%	10.00	17.00	18.00	26.00	34.00	37.00	39.00	28.00	21.00	14.00	16.00	17.00	19.00	17.00	15.00	17.00	17.00	17.00	14.00	12.00	11.00
Shareholder's Equity	-12.4%	45.00	52.00	20.00	21.00	22.00	49.00	83.00	117	136	148	155	155	155	49.00	30.00	41.00	31.00	30.00	32.00	35.00	34.00
Retained Earnings	-3.8%	-275	-265	-256	-248	-236	-202	-163	-124	-102	-88.18	-81.80	-77.50	-74.81	-71.96	-89.19	-77.36	-74.33	-73.52	-70.22	-67.16	-64.38
Additional Paid-In Capital	1.1%	327	324	284	277	265	259	254	249	246	244	242	240	238	128	127	126	113	111	110	110	106
Accumulated Depreciation	1.7%	4.00	4.00	4.00	-	-	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0%	146	146	92.00	89.00	83.00	81.00	81.00	80.00	80.00	80.00	80.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	78.00	-	-	-	311	-	-	-	690	-	-	-	162	-	-	-	68.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	6.2%	-5,650	-6,020	-9,492	-18,431	-25,555	-34,534	-20,878	-14,022	-3,946	-8,657	-806	-12,834	-2,589	659	-341	3,339	-2,416	-2,510	-955	-527	-2,496
Share Based Compensation	6.7%	3,634	3,407	4,685	4,551	3,838	4,845	4,326	2,911	2,125	1,880	1,363	1,900	1,002	785	665	685	682	614	524	468	496
Cashflow From Investing	-	-	-	787	5,974	-141	-285	-148	2,403	-185	2,198	-222	-142	-4.93	14,993	-32.32	-18.76	-32.87	-21.81	-33.57	-74.30	-
Cashflow From Financing	-100.4%	-150	36,974	2,118	5,172	2,268	1,556	667	154	43.00	204	232	-542	108,348	1,681	-1,432	9,517	832	412	-755	2,745	-585

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VERU Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Net revenues	$ 4,135,301	$ 6,585,967	$ 6,276,027	$ 9,093,761
Cost of sales	3,457,002	2,493,892	4,447,276	4,299,631
Gross profit	678,299	4,092,075	1,828,751	4,794,130
Operating expenses:
Research and development	2,986,791	17,860,701	4,636,841	38,471,828
Selling, general and administrative	7,580,340	12,834,494	15,881,771	30,380,359
Provision for credit losses		3,911,714		3,911,714
Impairment of intangible assets		3,900,000		3,900,000
Total operating expenses	10,567,131	38,506,909	20,518,612	76,663,901
Gain on sale of ENTADFI® assets			918,372
Operating loss	(9,888,832)	(34,414,834)	(17,771,489)	(71,869,771)
Non-operating income (expenses):
Interest expense	(145,310)	(697,693)	(310,267)	(1,570,923)
Change in fair value of derivative liabilities	21,000	1,200,000	19,000	530,000
Change in fair value of equity securities	(192,030)		(571,928)
Other income, net	361,226	56,994	442,318	277,926
Total non-operating income (expenses)	44,886	559,301	(420,877)	(762,997)
Loss before income taxes	(9,843,946)	(33,855,533)	(18,192,366)	(72,632,768)
Income tax expense (benefit)	182,002	(66,559)	109,563	(134,837)
Net loss	$ (10,025,948)	$ (33,788,974)	$ (18,301,929)	$ (72,497,931)
Net loss per basic common shares outstanding	$ (0.07)	$ (0.42)	$ (0.15)	$ (0.90)
Basic weighted average common shares outstanding	146,381,186	80,834,453	123,366,486	80,695,046
Net loss per diluted common shares outstanding	$ (0.07)	$ (0.42)	$ (0.15)	$ (0.90)
Diluted weighted average common shares outstanding	146,381,186	80,834,453	123,366,486	80,695,046

VERU Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 34,738,038	$ 9,625,494
Accounts receivable, net	2,785,331	4,506,508
Inventories, net	4,804,665	6,697,117
Prepaid research and development costs	924,583	1,006,252
Prepaid expenses and other current assets	1,884,684	1,097,851
Total current assets	45,137,301	22,933,222
Plant and equipment, net	1,534,196	1,652,732
Operating lease right-of-use assets	3,947,417	4,332,473
Investments in equity securities	346,444
Deferred income taxes	12,635,927	12,707,419
Goodwill	6,878,932	6,878,932
Other assets	1,320,142	1,518,313
Total assets	71,800,359	50,023,091
Current liabilities:
Accounts payable	2,464,135	12,931,172
Accrued compensation	2,683,214	990,609
Accrued expenses and other current liabilities	2,425,385	1,987,738
Residual royalty agreement liability, short-term portion	950,600	864,623
Operating lease liability, short-term portion	1,043,029	1,036,590
Total current liabilities	9,566,363	17,810,732
Residual royalty agreement liability, long-term portion	8,775,284	8,870,136
Operating lease liability, long-term portion	3,262,818	3,634,114
Other liabilities	4,986,250	29,948
Total liabilities	26,590,715	30,344,930
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock; no shares issued and outstanding at March 31, 2024 and September 30, 2023
Common stock, par value $0.01 per share; 308,000,000 shares authorized, 148,564,890 and 93,966,402 shares issued and 146,381,186 and 91,782,698 shares outstanding at March 31, 2024 and September 30, 2023, respectively	1,485,649	939,664
Additional paid-in-capital	327,182,257	283,894,830
Accumulated other comprehensive loss	(581,519)	(581,519)
Accumulated deficit	(275,070,138)	(256,768,209)
Treasury stock, 2,183,704 shares, at cost	(7,806,605)	(7,806,605)
Total stockholders' equity	45,209,644	19,678,161
Total liabilities and stockholders' equity	$ 71,800,359	$ 50,023,091

About Veru Inc

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

CEO	Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.
WEBSITE	verupharma.com
INDUSTRY	Biotechnology
EMPLOYEES	233

Veru Inc Frequently Asked Questions

What is the ticker symbol for Veru Inc? What does VERU stand for in stocks?

VERU is the stock ticker symbol of Veru Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veru Inc (VERU)?

As of Fri May 17 2024, market cap of Veru Inc is 190.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERU stock?

You can check VERU's fair value in chart for subscribers.

What is the fair value of VERU stock?

You can check VERU's fair value in chart for subscribers. The fair value of Veru Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Veru Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Veru Inc a good stock to buy?

The fair value guage provides a quick view whether VERU is over valued or under valued. Whether Veru Inc is cheap or expensive depends on the assumptions which impact Veru Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERU.

What is Veru Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VERU's PE ratio (Price to Earnings) is -4.88 and Price to Sales (PS) ratio is 14.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERU PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veru Inc's stock?

In the past 10 years, Veru Inc has provided -0.14 (multiply by 100 for percentage) rate of return.